Affiliation:
1. ICMR-National Institute of Cholera and Enteric Diseases
2. Johns Hopkins Bloomberg School of Public Health
Abstract
Abstract
The diagnostic assays currently used to detect Shigella spp. (Shigella) and enterotoxigenic Escherichia coli (ETEC) are complex or elaborate which make them difficult to apply in resource poor settings where these diseases are endemic. The simple and rapid nucleic acid amplification-based assay "Rapid LAMP-based Diagnostic Test (RLDT)" was evaluated to detect Shigella spp (Shigella) and enterotoxigenic Escherichia coli (ETEC) and determine the epidemiology of these pathogens in Kolkata, India. Stool samples (n = 405) from children under five years old with diarrhea seeking care at the hospitals were tested, and 85(21%) and 68(17%) by RLDT, 91(23%) and 58(14%) by quantitative PCR (qPCR) and 35(9%) and 15(4%) by culture, were positive for Shigella and ETEC, respectively. The RLDT showed almost perfect agreement with qPCR, Kappa 0.96 and 0.89; sensitivity 93% and 98%; specificity 100% and 97% for Shigella and ETEC, respectively. While RLDT detected 12% more Shigella and 13% more ETEC than culture, all culture positives for Shigella and ETEC except one each were also positive by the RLDT, sensitivity 97% and 93% respectively. RLDT is a simple, sensitive, and rapid assay that could be implemented with minimum training in the endemic regions to strengthen the disease surveillance system and rapid outbreak detection.
Publisher
Research Square Platform LLC
Reference25 articles.
1. Burden of enterotoxigenic Escherichia coli and Shigella non-fatal diarrhoeal infections in 79 low-income and lower middle-income countries: a modelling analysis;Anderson JD;The Lancet. Global health,2019
2. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study;Kotloff KL;Lancet (London, England),2013
3. Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy;Hosangadi D;Vaccine,2019
4. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology;Seidlein L;PLoS medicine,2006
5. Shigella isolates from the global enteric multicenter study inform vaccine development;Livio S;Clinical infectious diseases: an official publication of the Infectious Diseases Society of America,2014